- Home
- REPL
REPL
Replimune Group Inc.
as 11-21-2025 3:40pm EST
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | WOBURN |
| Market Cap: | 547.0M | IPO Year: | 2018 |
| Target Price: | $12.00 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.68 - $17.00 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Replimune Group Inc. (REPL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sarchi Christopher | REPL | Chief Commercial Officer | Nov 17 '25 | Sell | $9.10 | 5,208 | $47,392.80 | 123,088 | |
| Xynos Konstantinos | REPL | Chief Medical Officer | Nov 17 '25 | Sell | $9.10 | 7,248 | $65,956.80 | 139,685 |
Latest Replimune Group Inc. News
REPL Breaking Stock News: Dive into REPL Ticker-Specific Updates for Smart Investing
GlobeNewswire
15 days ago
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)
GlobeNewswire
16 days ago
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
MT Newswires
19 days ago
BMO Capital Upgrades Replimune Group to Market Perform From Underperform, Adjusts Price Target to $11 From $2
Simply Wall St.
a month ago
Replimune Group (REPL) Is Up 86.2% After FDA Accepts Resubmitted RP1 Application for Advanced Melanoma—Has The Bull Case Changed?
MT Newswires
a month ago
Piper Sandler Upgrades Replimune Group to Overweight From Neutral, Adjusts Price Target to $13 From $8
Simply Wall St.
a month ago
A Look at Replimune Group’s (REPL) Valuation Following Promising IGNYTE Phase 2 Melanoma Trial Results
Motley Fool
a month ago
Why Replimune Stock Was Soaring Today
MT Newswires
a month ago
JPMorgan Upgrades Replimune Group to Neutral From Underweight, $11 Price Target
Compare REPL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "REPL Replimune Group Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.